http://biostrat.dk BIOSTRAT specialises in assisting biotech companies in the Nordic region in making the right strategic decisions with regards to Business Development, M&A and Interim Management. Tue, 06 Dec 2011 15:44:57 +0000 http://backend.userland.com/rss092 en Undertegnede har stor erfaring med at skaffe kapital til iværksætter-virksomheder. Dette gælder både finansiering fra investorer til egne iværksætter-projekter men også som konsulent hvor jeg har hjulpet andre iværksættere med at skaffe kapital fra business angels, venture kapital fonde og offentlige fonde. På Kapitalblog.dk deler vi ud af vores erfaringer med ... http://biostrat.dk/funding/kapital-til-iv%c3%a6rks%c3%a6ttere/ Together with AVANCE, BIOSTRAT Biotech Consulting has completed an analysis in which it is determined which discount rates industry professionals in pharma and biotech are applying when doing financial valuations in drug development. The 242 respondents in the survey are widely distributed across the key biotech industry stakeholder groups in biotech/pharma valuations ... http://biostrat.dk/funding/discount-rates-in-drug-development/ In 2009 BIOSTRAT BIOTECH CONSULTING set out to explore and map the various answers the these questions. We wanted to understand better the reality of biotechnology valuation and to share this understanding with theorists and practitioners alike looking for an overview of the different viewpoints on and approaches to biotechnology ... http://biostrat.dk/valuation-methods/financial-valuation-methods-for-biotechnology-biotech-insights-1/ Which discount rate and which valuation method to use is a hot topic when making financial valuations of biotech projects and biotech companies. Discount rates and valuation methods for biotech companies has been the subject of much theorizing. Methods as DCF, rNPV, and Real Options are methods known to most industry ... http://biostrat.dk/licensing/valuation-methods-and-discount-rates-in-biotech/ Analysts are advising investors to stay away from biotech companies in urgent need of capital. Goldman Sachs is predicting that as many as half of European biotech companies may fail due to the current credit crisis. We agree biotech companies having to raise capital in the next 12 months will either ... http://biostrat.dk/licensing/important-to-distinguish-between-the-short-term-and-longer-term-effects-of-the-credit-crisis/ BIOSTRAT has created a new networking group at Linkedin for Life Science professionals in Medicon Valley in both Denmark and Sweden. The group is open for all working in the Pharmaceutical, Biotech and Medtech industries in the region. To join the group (which is of course free), go to the following ... http://biostrat.dk/medicon-valley/new-medicon-valley-network-at-linkedin/ This week brought two good news for the biotech industry in Medicon Valley and the entire Nordic region: SwedenBio, the industry association for Swedish biotech companies, announced the yearly survey of the pharmaceutical pipeline in Sweden. The results are promissing - the drug development pipeline in Sweden has increased with 32 ... http://biostrat.dk/medicon-valley/pipeline-medicon-valley-venture-capital-funding/ The share-price of Lundbeck has fallen with approximately 10 %, since the Danish pharmaceutical company announced an inlicensing deal with the US biotech company Myriad for a new drug named Flurizan aimed against mild Alzheimer. Why do investors not like the deal, and could the deal be (yet another) good ... http://biostrat.dk/licensing/lundbeck-myriad-flurizan-licensing/